Buyer's Guide

Contact | Print version | PDF version | Recommend company

Portrait
AVONTEC is a biopharmaceutical company specialized in the development of novel nucleic acid based therapeutic treatments targeting transcription factors. Transcription factors are the master switches of gene regulation, able to turn genes on and off with exquisite sensitivity. The molecules developed at AVONTEC are designed to specifically attenuate abnormal transcription factor signaling, thereby normalizing the underlying cause of the disease. AVONTEC develops these decoy ODNs as therapeutic agents to treat chronic inflammation. AVONTEC’s lead programs, AVT-01 in asthma and AVT-02 UE in inflammatory skin diseases, have been successfully advanced into Phase IIa clinical trials that are expected to be completed within the first half of 2008. In addition, there are several candidates in the pipeline based on AVONTEC’s core decoy technology. AVONTEC operates based on a lean business model with a seasoned management team experienced in clinical development.

Industrial Sectors

Pharmacy